Welcome to 19 Conversations. Today we're asking Nathalie Moll, Director General of EFPIA, "How can we future-proof medicines regulation in the post-COVID world?". Listen to hear the discussion on this challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Catherine Boudot, Director of the Trademark Department, Servier "Fighting the fakes - what's industry's role?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Chris Skedgel, Director of Health Economics "Can a shared understanding of unmet medical needs support innovation?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Paul Robinson, European Patient Engagement Lead, MSD and Weronika Burkot, Patient Representative, International Diabetes Federation "Has COVID-19 transformed telemedicine forever?". Listen to hear their discussion on the challenge and how we're preparing for the future.  See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Johanna Mercier, Chief Commercial Officer, Gilead "How is the pharmaceutical industry contributing to the fight against COVID-19?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers (IFPMA) "Have you dropped the ball on antimicrobial resistance?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking David Jefferys, Senior Vice President for Global Regulatory, Healthcare Policy and Corporate Affairs, Eisai Europe and Chair of EFPIA's Alzheimer's disease platform and Philip Scheltens, Professor of Neurology and Director of the Alzheimer Centre in Amsterdam "Can we expect a cure for Alzheimer's soon?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Jack Scannell, Independent Consultant and Honorary Fellow at the School of Social and Political Science, The University of Edinburgh "Is the pharmaceutical industry making too much money?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Angelika Joos, Executive Director, Global Regulatory Policy, MSD "Can we develop better medicines for children faster?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.

Welcome to 19 Conversations. Today we're asking Elizabeth Hermsen, Head of Global Antimicrobial Stewardship, MSD and Bruce Altevogt, Vice President and Head of External Medical Engagement, Hospital Business Unit, Pfizer "Is industry doing enough to tackle antimicrobial resistance?". Listen to hear their discussion on the challenge and how we're preparing for the future. See acast.com/privacy for privacy and opt-out information.